<rss version="2.0">
  <channel>
    <title>Biopharmaceuticals &amp; Biotherapeutics Press Releases from SmartBrief</title>
    <link>http://www.smartbrief.com/news/FDLI/pressReleases.jsp?sb_code=RSS&amp;industry=Biopharmaceuticals%20%26%20Biotherapeutics</link>
    <description>Biopharmaceuticals &amp; Biotherapeutics Press Releases from SmartBrief</description>
    <item>
      <title>PDL BioPharma Announces Ex-Dividend Date of November 27 for Special Dividend</title>
      <link><![CDATA[http://www.smartbrief.com/news/FDLI/industryPR-detail.jsp?id=FF74FC22-7DFA-43AB-8315-29AE06F57641&amp;sb_code=RSS&amp;i=Biopharmaceuticals%20%26%20Biotherapeutics]]></link>
      <description></description>
      <pubDate>Mon, 23 Nov 2009 16:04:25 CST</pubDate>
    </item>
    <item>
      <title>StemCells, Inc. CEO Martin McGlynn Featured On BioBusiness.TV s  Stem Cell Review  Series</title>
      <link><![CDATA[http://www.smartbrief.com/news/FDLI/industryBW-detail.jsp?id=C124E3E6-6C0B-407E-B8A4-CEAB421B2AC6&amp;sb_code=RSS&amp;i=Biopharmaceuticals%20%26%20Biotherapeutics]]></link>
      <description>StemCells, Inc. (NASDAQ: STEM) announced today that its president and CEO, Martin McGlynn, was recently featured on BioBusiness.TV?s ?Stem Cell Review? discussing the Company?s therapeutic product development programs, including the promise of human ...</description>
      <pubDate>Mon, 23 Nov 2009 15:34:25 CST</pubDate>
    </item>
    <item>
      <title>Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients</title>
      <link><![CDATA[http://www.smartbrief.com/news/FDLI/industryPR-detail.jsp?id=784C5059-4944-4BD9-BE4E-CC873D9AEDCE&amp;sb_code=RSS&amp;i=Biopharmaceuticals%20%26%20Biotherapeutics]]></link>
      <description></description>
      <pubDate>Mon, 23 Nov 2009 09:34:25 CST</pubDate>
    </item>
    <item>
      <title>StemCells, Inc. Initiates Landmark Trial Targeting  Communication Highway  of the Brain</title>
      <link><![CDATA[http://www.smartbrief.com/news/FDLI/industryBW-detail.jsp?id=9CFC87D8-645D-4D2C-A823-066448E3145A&amp;sb_code=RSS&amp;i=Biopharmaceuticals%20%26%20Biotherapeutics]]></link>
      <description>StemCells, Inc. (NASDAQ: STEM) announced today that it has commenced patient recruitment for a Phase I clinical trial designed to test the safety and preliminary efficacy of its HuCNS-SCŪ purified human neural stem cells in Pelizaeus-Merzbacher Disea...</description>
      <pubDate>Mon, 23 Nov 2009 08:05:25 CST</pubDate>
    </item>
    <item>
      <title>Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors</title>
      <link><![CDATA[http://www.smartbrief.com/news/FDLI/industryBW-detail.jsp?id=2997ED74-42D9-4210-8D95-F2189CC278AF&amp;sb_code=RSS&amp;i=Biopharmaceuticals%20%26%20Biotherapeutics]]></link>
      <description>Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. today announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients ...</description>
      <pubDate>Mon, 23 Nov 2009 06:04:25 CST</pubDate>
    </item>
    <item>
      <title>Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director</title>
      <link><![CDATA[http://www.smartbrief.com/news/FDLI/industryPR-detail.jsp?id=62527D7D-0A84-4782-99F0-78ADF0482622&amp;sb_code=RSS&amp;i=Biopharmaceuticals%20%26%20Biotherapeutics]]></link>
      <description></description>
      <pubDate>Mon, 23 Nov 2009 05:34:25 CST</pubDate>
    </item>
  </channel>
</rss>
